Participant flow

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) · Source last updated 2022-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.

   id

   FG000

   title

   Nivolumab

2. description

   Docetaxel 75mg/m\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.

   id

   FG001

   title

   Docetaxel

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Adverse Event unrelated to study drug

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         6

      type

      Participant withdrew consent

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         2

      type

      No longer meets study criteria

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         135

      2. group Id

         FG001

         num Subjects

         137

      comment

      Started=Randomized

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         131

      2. group Id

         FG001

         num Subjects

         129

      comment

      Completed= participants that received treatment

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Randomization

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         95

      2. group Id

         FG001

         num Subjects

         79

      type

      Disease progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         13

      type

      Study drug toxicity

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         13

      type

      Adverse event unrelated to study drug

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         9

      type

      Maximum clinical benefit

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Poor/non-compliance

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      type

      No longer meets study criteria

   8. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         0

      type

      Other reasons

   9. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         3

      type

      Not reported

   10. reasons

       1. group Id

          FG000

          num Subjects

          6

       2. group Id

          FG001

          num Subjects

          4

       type

       Participant request to discontinue study treatment

   11. reasons

       1. group Id

          FG000

          num Subjects

          5

       2. group Id

          FG001

          num Subjects

          5

       type

       Participant withdrew consent

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         131

      2. group Id

         FG001

         num Subjects

         129

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         6

      type

      Participants Transitioned to Nivolumab

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      comment

      Completed = continue in the treatment period

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         131

      2. group Id

         FG001

         num Subjects

         129

      type

      NOT COMPLETED

   title

   Treatment

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice